{"id":4231,"date":"2025-07-10T11:03:35","date_gmt":"2025-07-10T15:03:35","guid":{"rendered":"https:\/\/happylungsproject.org\/?p=4231"},"modified":"2026-03-02T10:52:37","modified_gmt":"2026-03-02T15:52:37","slug":"ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials","status":"publish","type":"post","link":"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/","title":{"rendered":"Ellipses\u2019 RET inhibitor EP0031 advances to Phase 2 clinical trials"},"content":{"rendered":"[vc_row type=”in_container” full_screen_row_position=”middle” column_margin=”default” column_direction=”default” column_direction_tablet=”default” column_direction_phone=”default” scene_position=”center” text_color=”dark” text_align=”left” row_border_radius=”none” row_border_radius_applies=”bg” overflow=”visible” overlay_strength=”0.3″ gradient_direction=”left_to_right” shape_divider_position=”bottom” bg_image_animation=”none” shape_type=””][vc_column column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” column_element_direction_desktop=”default” column_element_spacing=”default” desktop_text_alignment=”default” tablet_text_alignment=”default” phone_text_alignment=”default” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_backdrop_filter=”none” column_shadow=”none” column_border_radius=”none” column_link_target=”_self” column_position=”default” gradient_direction=”left_to_right” overlay_strength=”0.3″ width=”1\/1″ tablet_width_inherit=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid”][vc_row_inner column_margin=”default” column_direction=”default” column_direction_tablet=”default” column_direction_phone=”default” text_align=”left” row_position=”default” row_position_tablet=”inherit” row_position_phone=”inherit” overflow=”visible” pointer_events=”all”][vc_column_inner column_padding=”padding-3-percent” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” column_element_direction_desktop=”default” column_element_spacing=”default” desktop_text_alignment=”default” tablet_text_alignment=”default” phone_text_alignment=”default” background_color=”#f68d28″ background_color_opacity=”1″ background_hover_color_opacity=”1″ column_backdrop_filter=”none” font_color=”#ffffff” column_shadow=”none” column_border_radius=”10px” column_link_target=”_self” overflow=”visible” gradient_direction=”left_to_right” overlay_strength=”0.3″ width=”1\/1″ tablet_width_inherit=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid” column_padding_type=”default” gradient_type=”default”][vc_column_text css=”” text_direction=”default”]Ellipses\u2019 next generation selective RET inhibitor EP0031 advances to Phase 2 clinical trials in the USA.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner column_margin=”default” column_direction=”default” column_direction_tablet=”default” column_direction_phone=”default” text_align=”left” row_position=”default” row_position_tablet=”inherit” row_position_phone=”inherit” overflow=”visible” pointer_events=”all”][vc_column_inner column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” column_element_direction_desktop=”default” column_element_spacing=”default” desktop_text_alignment=”default” tablet_text_alignment=”default” phone_text_alignment=”default” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_backdrop_filter=”none” column_shadow=”none” column_border_radius=”none” column_link_target=”_self” overflow=”visible” gradient_direction=”left_to_right” overlay_strength=”0.3″ width=”1\/1″ tablet_width_inherit=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid”][vc_column_text css=”” text_direction=”default”]\n

Clinical study for patients with RET+ solid tumors<\/h3>\n

\"RET<\/a>EP0031\u00a0is a new specific RET inhibitor with broad activity against common RET fusions and mutations, including RET mutations that confer resistance to the RET inhibitors selpercatinib or pralsetinib and\u00a0great brain penetration.<\/p>\n

More info:<\/p>\n

Infographic PDF<\/a><\/p>\n

https:\/\/clinicaltrials.gov\/study\/NCT05443126<\/a><\/p>\n

2025 ASCO RET highlights<\/a><\/p>\n

 <\/p>\nMatch to a clinical trial<\/span><\/a>\nLearn more about RET research<\/span><\/a>[\/vc_column_text][vc_column_text css=”” text_direction=”default”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner column_margin=”default” column_direction=”default” column_direction_tablet=”default” column_direction_phone=”default” text_align=”left” row_position=”default” row_position_tablet=”inherit” row_position_phone=”inherit” overflow=”visible” pointer_events=”all”][vc_column_inner column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” column_element_direction_desktop=”default” column_element_spacing=”default” desktop_text_alignment=”default” tablet_text_alignment=”default” phone_text_alignment=”default” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_backdrop_filter=”none” column_shadow=”none” column_border_radius=”none” column_link_target=”_self” overflow=”visible” gradient_direction=”left_to_right” overlay_strength=”0.3″ width=”1\/4″ tablet_width_inherit=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid”][\/vc_column_inner][vc_column_inner column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” column_element_direction_desktop=”default” column_element_spacing=”default” desktop_text_alignment=”default” tablet_text_alignment=”default” phone_text_alignment=”default” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_backdrop_filter=”none” column_shadow=”none” column_border_radius=”none” column_link_target=”_self” overflow=”visible” gradient_direction=”left_to_right” overlay_strength=”0.3″ width=”1\/4″ tablet_width_inherit=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid”][\/vc_column_inner][vc_column_inner column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” column_element_direction_desktop=”default” column_element_spacing=”default” desktop_text_alignment=”default” tablet_text_alignment=”default” phone_text_alignment=”default” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_backdrop_filter=”none” column_shadow=”none” column_border_radius=”none” column_link_target=”_self” overflow=”visible” gradient_direction=”left_to_right” overlay_strength=”0.3″ width=”1\/4″ tablet_width_inherit=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid”][\/vc_column_inner][vc_column_inner column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” column_element_direction_desktop=”default” column_element_spacing=”default” desktop_text_alignment=”default” tablet_text_alignment=”default” phone_text_alignment=”default” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_backdrop_filter=”none” column_shadow=”none” column_border_radius=”none” column_link_target=”_self” overflow=”visible” gradient_direction=”left_to_right” overlay_strength=”0.3″ width=”1\/4″ tablet_width_inherit=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid”][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]\n","protected":false},"excerpt":{"rendered":"

Ellipses\u2019 next generation selective RET inhibitor EP0031 advances to Phase 2 clinical trials in the USA. RET + solid tumors.<\/p>\n","protected":false},"author":15,"featured_media":4232,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22,10],"tags":[],"class_list":{"0":"post-4231","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-clinical-trials","8":"category-research"},"yoast_head":"\nEllipses\u2019 RET inhibitor EP0031 advances to Phase 2 clinical trials<\/title>\n<meta name=\"description\" content=\"Ellipses\u2019 next generation selective RET inhibitor EP0031 advances to Phase 2 clinical trials in the USA. RET + solid tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ellipses\u2019 RET inhibitor EP0031 advances to Phase 2 clinical trials\" \/>\n<meta property=\"og:description\" content=\"Ellipses\u2019 next generation selective RET inhibitor EP0031 advances to Phase 2 clinical trials in the USA. RET + solid tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"The Happy Lungs Project\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/thehappylungsproject\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-10T15:03:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-02T15:52:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/happylungsproject.org\/wp-content\/uploads\/2025\/07\/RET-clinical-study-phase-2-ellipses.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2000\" \/>\n\t<meta property=\"og:image:height\" content=\"1127\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Irene Guijarro Munoz\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Irene Guijarro Munoz\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/\"},\"author\":{\"name\":\"Irene Guijarro Munoz\",\"@id\":\"https:\/\/happylungsproject.org\/#\/schema\/person\/7f7dfd38ae877d303fc9831b49693d4b\"},\"headline\":\"Ellipses\u2019 RET inhibitor EP0031 advances to Phase 2 clinical trials\",\"datePublished\":\"2025-07-10T15:03:35+00:00\",\"dateModified\":\"2026-03-02T15:52:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/\"},\"wordCount\":1020,\"publisher\":{\"@id\":\"https:\/\/happylungsproject.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/happylungsproject.org\/wp-content\/uploads\/2025\/07\/RET-clinical-study-phase-2-ellipses.jpg\",\"articleSection\":[\"Clinical Trials\",\"Research\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/\",\"url\":\"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/\",\"name\":\"Ellipses\u2019 RET inhibitor EP0031 advances to Phase 2 clinical trials\",\"isPartOf\":{\"@id\":\"https:\/\/happylungsproject.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/happylungsproject.org\/wp-content\/uploads\/2025\/07\/RET-clinical-study-phase-2-ellipses.jpg\",\"datePublished\":\"2025-07-10T15:03:35+00:00\",\"dateModified\":\"2026-03-02T15:52:37+00:00\",\"description\":\"Ellipses\u2019 next generation selective RET inhibitor EP0031 advances to Phase 2 clinical trials in the USA. RET + solid tumors.\",\"breadcrumb\":{\"@id\":\"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/#primaryimage\",\"url\":\"https:\/\/happylungsproject.org\/wp-content\/uploads\/2025\/07\/RET-clinical-study-phase-2-ellipses.jpg\",\"contentUrl\":\"https:\/\/happylungsproject.org\/wp-content\/uploads\/2025\/07\/RET-clinical-study-phase-2-ellipses.jpg\",\"width\":2000,\"height\":1127,\"caption\":\"RET clinical study phase 2 ellipses\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/happylungsproject.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ellipses\u2019 RET inhibitor EP0031 advances to Phase 2 clinical trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/happylungsproject.org\/#website\",\"url\":\"https:\/\/happylungsproject.org\/\",\"name\":\"The Happy Lungs Project\",\"description\":\"Finding dependable treatments and ultimately a cure for RET Positive NSCLC.\",\"publisher\":{\"@id\":\"https:\/\/happylungsproject.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/happylungsproject.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/happylungsproject.org\/#organization\",\"name\":\"The Happy Lungs Project\",\"url\":\"https:\/\/happylungsproject.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/happylungsproject.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/happylungsproject.org\/wp-content\/uploads\/2021\/07\/HAPPY-LUNGS-LOGOS_stacked-full-color-e1632760868380.png\",\"contentUrl\":\"https:\/\/happylungsproject.org\/wp-content\/uploads\/2021\/07\/HAPPY-LUNGS-LOGOS_stacked-full-color-e1632760868380.png\",\"width\":1500,\"height\":1575,\"caption\":\"The Happy Lungs Project\"},\"image\":{\"@id\":\"https:\/\/happylungsproject.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/thehappylungsproject\",\"https:\/\/www.instagram.com\/thehappylungsproject\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/happylungsproject.org\/#\/schema\/person\/7f7dfd38ae877d303fc9831b49693d4b\",\"name\":\"Irene Guijarro Munoz\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/happylungsproject.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b203420602dc287c938d2e2de2a2da59b7a2f94264288a3f345af4be6737c07a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b203420602dc287c938d2e2de2a2da59b7a2f94264288a3f345af4be6737c07a?s=96&d=mm&r=g\",\"caption\":\"Irene Guijarro Munoz\"},\"description\":\"Irene Guijarro Munoz, Director of Research Irene Guijarro Munoz joined the Happy Lungs Project (HLP) as Director of Research in 2022. She oversees and coordinates the RET research program at HLP, including the studies that are currently being funded by HLP and conducted at four major US cancer centers. She assists with the development of RET research funding proposals and coordinates collaborations between the academic investigators and commercial contractors. In addition, she helps lung cancer patients and their families in the understanding of the RET positive lung cancer biology and the potential treatment options available. She has a scientific background and she completed a PhD in Biochemistry, Molecular Biology and Biomedicine, a Master of Biotechnology, and a Bachelor\u2019s Degree in Biochemistry at Universidad Aut\u00f3noma de Madrid, Spain, where she is originally from.\",\"sameAs\":[\"https:\/\/happylungsproject.org\/irene-our-director-of-ret-lung-cancer-research\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ellipses\u2019 RET inhibitor EP0031 advances to Phase 2 clinical trials","description":"Ellipses\u2019 next generation selective RET inhibitor EP0031 advances to Phase 2 clinical trials in the USA. RET + solid tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/","og_locale":"en_US","og_type":"article","og_title":"Ellipses\u2019 RET inhibitor EP0031 advances to Phase 2 clinical trials","og_description":"Ellipses\u2019 next generation selective RET inhibitor EP0031 advances to Phase 2 clinical trials in the USA. RET + solid tumors.","og_url":"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/","og_site_name":"The Happy Lungs Project","article_publisher":"https:\/\/www.facebook.com\/thehappylungsproject","article_published_time":"2025-07-10T15:03:35+00:00","article_modified_time":"2026-03-02T15:52:37+00:00","og_image":[{"width":2000,"height":1127,"url":"https:\/\/happylungsproject.org\/wp-content\/uploads\/2025\/07\/RET-clinical-study-phase-2-ellipses.jpg","type":"image\/jpeg"}],"author":"Irene Guijarro Munoz","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Irene Guijarro Munoz","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/#article","isPartOf":{"@id":"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/"},"author":{"name":"Irene Guijarro Munoz","@id":"https:\/\/happylungsproject.org\/#\/schema\/person\/7f7dfd38ae877d303fc9831b49693d4b"},"headline":"Ellipses\u2019 RET inhibitor EP0031 advances to Phase 2 clinical trials","datePublished":"2025-07-10T15:03:35+00:00","dateModified":"2026-03-02T15:52:37+00:00","mainEntityOfPage":{"@id":"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/"},"wordCount":1020,"publisher":{"@id":"https:\/\/happylungsproject.org\/#organization"},"image":{"@id":"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/happylungsproject.org\/wp-content\/uploads\/2025\/07\/RET-clinical-study-phase-2-ellipses.jpg","articleSection":["Clinical Trials","Research"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/","url":"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/","name":"Ellipses\u2019 RET inhibitor EP0031 advances to Phase 2 clinical trials","isPartOf":{"@id":"https:\/\/happylungsproject.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/#primaryimage"},"image":{"@id":"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/happylungsproject.org\/wp-content\/uploads\/2025\/07\/RET-clinical-study-phase-2-ellipses.jpg","datePublished":"2025-07-10T15:03:35+00:00","dateModified":"2026-03-02T15:52:37+00:00","description":"Ellipses\u2019 next generation selective RET inhibitor EP0031 advances to Phase 2 clinical trials in the USA. RET + solid tumors.","breadcrumb":{"@id":"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/#primaryimage","url":"https:\/\/happylungsproject.org\/wp-content\/uploads\/2025\/07\/RET-clinical-study-phase-2-ellipses.jpg","contentUrl":"https:\/\/happylungsproject.org\/wp-content\/uploads\/2025\/07\/RET-clinical-study-phase-2-ellipses.jpg","width":2000,"height":1127,"caption":"RET clinical study phase 2 ellipses"},{"@type":"BreadcrumbList","@id":"https:\/\/happylungsproject.org\/ellipses-ret-inhibitor-ep0031-advances-to-phase-2-clinical-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/happylungsproject.org\/"},{"@type":"ListItem","position":2,"name":"Ellipses\u2019 RET inhibitor EP0031 advances to Phase 2 clinical trials"}]},{"@type":"WebSite","@id":"https:\/\/happylungsproject.org\/#website","url":"https:\/\/happylungsproject.org\/","name":"The Happy Lungs Project","description":"Finding dependable treatments and ultimately a cure for RET Positive NSCLC.","publisher":{"@id":"https:\/\/happylungsproject.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/happylungsproject.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/happylungsproject.org\/#organization","name":"The Happy Lungs Project","url":"https:\/\/happylungsproject.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/happylungsproject.org\/#\/schema\/logo\/image\/","url":"https:\/\/happylungsproject.org\/wp-content\/uploads\/2021\/07\/HAPPY-LUNGS-LOGOS_stacked-full-color-e1632760868380.png","contentUrl":"https:\/\/happylungsproject.org\/wp-content\/uploads\/2021\/07\/HAPPY-LUNGS-LOGOS_stacked-full-color-e1632760868380.png","width":1500,"height":1575,"caption":"The Happy Lungs Project"},"image":{"@id":"https:\/\/happylungsproject.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/thehappylungsproject","https:\/\/www.instagram.com\/thehappylungsproject\/"]},{"@type":"Person","@id":"https:\/\/happylungsproject.org\/#\/schema\/person\/7f7dfd38ae877d303fc9831b49693d4b","name":"Irene Guijarro Munoz","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/happylungsproject.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b203420602dc287c938d2e2de2a2da59b7a2f94264288a3f345af4be6737c07a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b203420602dc287c938d2e2de2a2da59b7a2f94264288a3f345af4be6737c07a?s=96&d=mm&r=g","caption":"Irene Guijarro Munoz"},"description":"Irene Guijarro Munoz, Director of Research Irene Guijarro Munoz joined the Happy Lungs Project (HLP) as Director of Research in 2022. She oversees and coordinates the RET research program at HLP, including the studies that are currently being funded by HLP and conducted at four major US cancer centers. She assists with the development of RET research funding proposals and coordinates collaborations between the academic investigators and commercial contractors. In addition, she helps lung cancer patients and their families in the understanding of the RET positive lung cancer biology and the potential treatment options available. She has a scientific background and she completed a PhD in Biochemistry, Molecular Biology and Biomedicine, a Master of Biotechnology, and a Bachelor\u2019s Degree in Biochemistry at Universidad Aut\u00f3noma de Madrid, Spain, where she is originally from.","sameAs":["https:\/\/happylungsproject.org\/irene-our-director-of-ret-lung-cancer-research\/"]}]}},"_links":{"self":[{"href":"https:\/\/happylungsproject.org\/wp-json\/wp\/v2\/posts\/4231","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/happylungsproject.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/happylungsproject.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/happylungsproject.org\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/happylungsproject.org\/wp-json\/wp\/v2\/comments?post=4231"}],"version-history":[{"count":8,"href":"https:\/\/happylungsproject.org\/wp-json\/wp\/v2\/posts\/4231\/revisions"}],"predecessor-version":[{"id":4241,"href":"https:\/\/happylungsproject.org\/wp-json\/wp\/v2\/posts\/4231\/revisions\/4241"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/happylungsproject.org\/wp-json\/wp\/v2\/media\/4232"}],"wp:attachment":[{"href":"https:\/\/happylungsproject.org\/wp-json\/wp\/v2\/media?parent=4231"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/happylungsproject.org\/wp-json\/wp\/v2\/categories?post=4231"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/happylungsproject.org\/wp-json\/wp\/v2\/tags?post=4231"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}